United States: The Patent Office Clarifies The Ban On Patenting Naturally-Derived Drugs And Other Products

Last Updated: January 6 2015
Article by Nicholas J. Landau, Ph.D

Since the very beginning of America's revolutionary patent system, inventors in the life sciences have been granted patents for discovering and purifying natural products. It was taken as a given that a purified natural product could be patented, so long as that natural product had never existed in a purified state before. Classic examples include Louis Pasteur's patent for a pure yeast culture, Jokichi Takamine's patent for adrenaline, and Selman Waksman's numerous patents for natural antibiotics such as streptomycin. However, last year the U.S. Supreme Court banned the patenting of purified DNA in its landmark decision Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 12 (2013) (commonly known as "Myriad"). This abrupt reversal of age-old law left many wondering if the ban extends to all naturally occurring substances, such as drugs from natural sources, biomarkers, DNA molecules, antibodies, enzymes, cultures, PCR primers, and nutrients.

The USPTO's First Response to Myriad

It is the duty of the United States Patent and Trademark Office (USPTO) to ascertain whether an invention for which one seeks a patent is eligible for a patent. In response to the Myriad ban, the USPTO issued a set of guidelines to its patent examiners in March of 2014. The March guidelines were controversial and widely criticized. They created a complex approach in which examiners must answer 16 questions and weigh the answers of each against one another to determine whether an invention falls under the Myriad ban. The March guidelines also contained odd and surprising conclusions, such as that gunpowder is a "natural product" that could not have been patented when it was invented (had there been a patent system). In sum the March guidelines provided no clarity to the regulated public as to what life sciences inventions apart from DNA are subject to the Supreme Court's new ban.

The USPTO Reconsiders its Initial Approach

The USPTO took these criticisms to heart, and on December 16th it revoked the March guidelines and published a set of proposed new guidelines in the Federal Register (Fed. Reg. vol. 79, No. 241, p. 74618). The public has been given until March 16, 2015, to submit comments to the new guidelines. In light of such comments the USPTO may revise the guidelines before making them final. The USPTO's guidelines are not laws; if challenged in a court of law the court will give them no deference. However, as most patent applicants prefer to avoid recourse to the courts in pursuit of a patent, whatever guidelines are adopted in final form will have a deep impact on the ability of life sciences companies to obtain patent protection for their inventions.

Natural Products Must Pass a Three-Step Test

The USPTO has replaced the 16-question analysis with a more straightforward three-step test, illustrated in a simple flowchart. The first step is to determine whether the invention in a given patent claim meets the requirement actually found in the Patent Act that one may only patent a process, machine, manufacture, or composition of matter. This is a clear and simple test, as anything composed of matter is a "composition of matter," and anything that involves one or more defined human actions is a "process." If the patent claim is in one of these categories, then the next step is to determine whether the invention is subject to one of the judge-made bans on patenting.

In the context of the life sciences, the second step will address whether any part of the invention involves a natural substance. This test really has two sub-parts. The first sub-part merely involves identifying a substance in the invention that can be considered natural. The second sub-part is determining whether the natural substance in the invention is somehow "markedly different" from how it is found in nature. The guidance states that the marked difference must be a difference in structure, function, or another property. Importantly, the guidance clearly states that a purified natural substance can be patented if the purified form is markedly different from the natural form in one of these three ways. Examples of the marked difference are a difference in pharmacological function, a difference in structure, a difference in chemical properties, a difference in physical properties, or a difference in "form." If the invention is "markedly different" from what is natural, then the ban does not apply. If it is not, then a third step must be performed.

The third is determining whether the invention as a whole is something "significantly more" than the natural substance. The term "significantly more" is inherently subjective, but is further defined to mean that the use of the natural substance is limited so that not all possible uses of the substance are patented. Examples of such limited uses are provided, including an improvement to a pre-existing technology, use of the substance with a particular machine, use of the substance in a transformation of a physical thing to another state or thing, use in a way that is not conventional and well-understood, and use in a specific useful application. Merely stating that the invention is intended for a specific field of use is not sufficient to overcome the ban.

Specific Examples of Patent Claims for Natural Substances

The guidance contains several specific examples of inventions involving natural substances, and provides opinions in each case as to whether the example violates the Myriad ban. One example is of a specific machine that is coated with a natural mineral. Because the mineral is used with a specific machine, the invention is "significantly more" than just the mineral, and the ban does not apply.

Another example is of a bacterium that has been genetically modified (GM) to contain two hydrocarbon metabolic pathways. Although the bacterium is a natural product, the GM bacterium has a markedly different function from the bacterium found in its natural state: the GM bacterium can metabolize two hydrocarbons, whereas the natural bacterium can only metabolize one. The GM bacterium also has a markedly different structure than a natural bacterium, by virtue of having the genes for the two metabolic pathways. Thus the ban does not apply.

Another example provided is the invention in the Myriad case, which was an isolated DNA molecule encoding the BRCA1 protein. In that case, the Supreme Court decided that the invention is banned from patenting. The molecule is a "composition of matter" as permitted by the Act (step 1). As a type of molecule that occurs in nature it is a "natural product;" the Court found that the isolated DNA is not "markedly different" from the natural DNA, because it has the same structure and serves the same function. Finally, there is no limitation on how the DNA can be used, so the invention is not "significantly more" than just the natural DNA. Therefore the guidance reaches the conclusion that it is banned from patenting.

What Should Life Sciences Inventors Do?

The new guidance is an improvement in that it creates an understandable framework for applying the Myriad ban. However, this does not change the underlying fact that the United States may now be the most hostile country in the world to life sciences inventions. New difficulties will be encountered for inventions in the areas of drugs, biologics (including antibodies and vaccines), dietary supplements, food additives, enzymes, nutrients, primers for PCR, and biomarkers. Several of these have been interpreted as banned from patenting by lower court decisions since Myriad.

However, one should not necessarily forgo attempts to protect such inventions for the following reasons.

Countries outside of the United States have not shown any interest in following the U.S.'s lead in creating this new patenting ban. Although the United States remains the world's largest market in terms of nominal GDP, the European Union (EU) as a whole exceeds the GDP of the U.S. In sum, the EU, mainland China, and Japan have a GDP that is slightly less than twice that of the United States. These foreign markets remain quite lucrative and permit purified natural substances to be patented, so consider retaining the ability to claim these types of inventions in foreign countries. Based on the increased patenting risk in the U.S., consider shifting research focus to problems that are consequential in major markets outside of the U.S., and away from problems that are unique to the U.S. or primarily of consequence in the U.S.

Instead of patenting, certain types of inventions can be protected as trade secrets. As the U.S. weakens its patent laws, trade secrecy is becoming a more popular form of IP protection for all types of inventions. The Myriad ban is yet another push in the direction of secrecy for life sciences inventions.

Before patenting, publishing, or presenting newly identified genes or other useful natural substances, serious consideration should be given to maintaining the invention in strict secrecy until its commercial potential can be ascertained, so that patent applications can be filed for all commercially viable, artificially modified, forms. For drugs, biologics, and medical devices, trade secrecy is generally impractical, because of the need to obtain regulatory approval from the U.S. Food and Drug Administration. If the substance could be useful in an industry outside of those which have governmentally mandated rules of public disclosure, then consideration should be given to maintaining the invention as a permanent trade secret.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.